GLUE Reports $671M Cash, $19B Revenue, +94% CRP Drop, Phase 2 Initiations in H2 2026
Monte Rosa Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $19.67
-9.1% in 7d after detection
Post-detection moves
1h
—
1d
-2.1%
3d
-3.5%
7d
-9.1%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS